Meeder Asset Management Inc Fennec Pharmaceuticals Inc. Transaction History

Meeder Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 09, 2021	SELL	$5.99 - $8.55 $7,846 - $11,200	-1,310 Closed	0 $0
Q2 2020 Aug 11, 2020	SELL	$5.43 - $9.39 $2,877 - $4,976	-530 Reduced 28.8%	1,310 $11,000
Q1 2020 May 15, 2020	SELL	$4.89 - $8.1 $24,029 - $39,803	-4,914 Reduced 72.76%	1,840 $11,000
Q3 2019 Oct 17, 2019	BUY	$3.85 - $4.95 $7,873 - $10,122	2,045 Added 43.43%	6,754 $32,000
Q2 2019 Aug 05, 2019	SELL	$3.3 - $5.09 $15,163 - $23,388	-4,595 Reduced 49.39%	4,709 $19,000
Q1 2019 Apr 16, 2019	SELL	$4.64 - $7.58 $2,023 - $3,304	-436 Reduced 4.48%	9,304 $44,000
Q4 2018 Jan 17, 2019	BUY	$5.37 - $8.39 $3,952 - $6,175	736 Added 8.17%	9,740 $62,000
Q3 2018 Nov 02, 2018	BUY	$7.84 - $10.83 $70,591 - $97,513	9,004 New	9,004 $0

14.8M

10K

83.8K

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $151M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.